Kuhnil to sign an exclusive distribution of anticancer drug with Regulon Inc.
Published: 2005-09-09 06:57:00
Updated: 2005-09-09 06:57:00
Kuhnil announced on Sept. 6 that an agreement was signed with Regulon Inc. for the exclusive distribution of an anti-cancer drug, Lipoplatin, in Korea, which is a lipsome preparation of Cisplastin, showing better profiles of its toxicity.
Regulon Inc. said that Lipoplatin provided a better qu...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
